Hadassah

Hadassah Identifies Gene Mutation Behind Rare Disease of Fat Metabolism

Thursday, Sep 13 2018

When the woman we can call “HA” applied for a permit to come to Hadassah Hospital from Gaza, she didn’t know that she would be making a significant contribution to the Hadassah Medical Organization’s understanding of the genetics of lipid metabolism.

HA had not yet been diagnosed with the extremely rare disease named Congenital Generalized Lipodystrophy (CGL).

Lipodystrophies are a group of unusual diseases characterized by partial or generalized loss or absence of fat. CGL’s characteristic clinical feature is near total lack of body fat and extreme muscularity, present at birth. These individuals--estimated worldwide at about one in ten million--develop extremely high levels of triglycerides, insulin resistance, and associated complications, such as diabetes mellitus, fatty liver disease, polycystic ovary syndrome, and hypertension. The genes involved in CGL have a role in the differentiation and function of fat cells, and the processing of fat in other tissues. Hadassah’s patient had a total cholesterol of 1,314, triglycerides of over 8,000, and an LDL of 1,260!

Once Hadassah cardiologist Dr. Ronen Durst, along with medical student Koby Gorin, made the diagnosis, they evaluated the patient’s family with the aim of determining the specific mutation. They found six affected family members and identified a novel frameshift mutation in the AGPAT2 gene.

AGPAT2, located on chromosome number nine, encodes an enzyme that is a key intermediate in the biosynthesis of fats in the body. The Hadassah team is working to understand the molecular mechanism of this gene, which will broaden understanding of fat metabolism in this disease and in the general population.

Currently, the most effective treatment for CGL is recombinant leptin, which can lead to a reduction in triglyceride levels and insulin resistance. Perhaps, the cardiology researchers note, their work will eventually lead to a genetic therapy for CGL and other avenues for treatment of abnormalities in fat metabolism.

Learn more about the Hadassah Medical Organization.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, Jun 19 2019

Happiness in the Intensive Care Unit: A Father Expresses His Anticipatory Joy

“My name is Yoel Fadel. Today is a very special day for me. My youngest son, Benny, is getting married. He will walk to the wedding canopy with his sweetheart, but I cannot attend the wedding.

READ MORE ›
alt_text

Wednesday, Jun 19 2019

Helping with a Full Heart: A Mitzvah Passed on at Hadassah Mount Scopus

They met in the Pediatrics Department at Hadassah Hospital Mount Scopus, two couples whose children suffer from a rare disease.

READ MORE ›
alt_text

Tuesday, Jun 18 2019

Diabetes: An Ongoing Struggle

Prof. Gil Leibowitz, head of the Diabetes Unit at the Hadassah Medical Organization’s Endocrinology and Metabolism Service, remembers himself as a scared, skinny seven-year-old when the doctor told his parents that he had type 1 diabetes.

READ MORE ›
alt_text

Wednesday, Jun 12 2019

Multinational Study Reveals Reduction in Kidney Disease Progression with Diabetes Drug

In a large multinational study that revealed the effectiveness of a medicine called dapagliflozin in reducing cardiovascular death from heart failure among high-risk diabetic patients, the first sub-analysis of renal data has also identified a 47 percent drop in decline of kidney function and renal death.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More